Pen-G ramp-up delays
Pen-G plant faced teething problems in Q1; any further delays could impact margin improvement expectations.
high · management_commentary
Aurobindo Pharma Limited — Q1 FY25
Aurobindo Pharma reported a solid Q1 FY25 with revenue of INR 7,567 crore (+10% YoY) and PAT of INR 919 crore (+61% YoY), driven by strong performance in Europe (EUR 221 million...
bullish
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Injectables remediation and FDA compliance
Eugia Unit III remediation cost $9M in Q1; Bhiwadi plant received OAI. Further regulatory actions could disrupt injectable sales.
high · analyst_questionUS price erosion and competition
Management expects current US pricing scenario to continue; low single-digit price erosion in injectables could pressure margins.
medium · management_commentaryBiosimilar approval delays
Biosimilar filings with EMA and FDA are subject to regulatory uncertainties; delays could push revenue contribution beyond FY26.
medium · management_commentary